Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Published:2011-07-01 Issue:7 Volume:121 Page:2750-2767
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Lehmann Brian D.,Bauer Joshua A.,Chen Xi,Sanders Melinda E.,Chakravarthy A. Bapsi,Shyr Yu,Pietenpol Jennifer A.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference78 articles.

1. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

2. Phase-II trial of tamoxifen in advanced breast cancer

3. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

4. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients

5. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

Cited by 4100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy;Biomaterials;2025-01

2. Multi-layered knowledge graph neural network reveals pathway-level agreement of three breast cancer multi-gene assays;Computational and Structural Biotechnology Journal;2024-12

3. Insights into multidrug resistance mechanisms: Exploring distinct miRNAs as prospective therapeutic agents in triple negative breast cancer;Gene Reports;2024-12

4. Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo;Translational Oncology;2024-11

5. Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer;European Journal of Medicinal Chemistry;2024-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3